US · EBS
Emergent BioSolutions Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Gaithersburg, MD 20879
- Website
- emergentbiosolutions.com
Price · as of 2025-12-31
$8.47
Market cap 434.81M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $47.34 | +458.91% |
| Intrinsic Value(DCF) | $3.60 | -57.5% |
| Graham-Dodd Method(GD) | $14.68 | +73.36% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $16.00 | $64.43 | $14.05 | $14.69 | $2.53 |
| 2012 | $15.49 | $33.09 | $2.51 | $15.34 | $7.30 |
| 2013 | $27.77 | $40.93 | $3.39 | $17.44 | $16.04 |
| 2014 | $29.21 | $88.96 | $90.05 | $18.61 | $35.67 |
| 2015 | $34.00 | $98.08 | $126.48 | $23.82 | $45.97 |
| 2016 | $31.05 | $68.57 | $42.23 | $20.26 | $10.23 |
| 2017 | $52.49 | $68.55 | $25.03 | $30.52 | $44.02 |
| 2018 | $56.93 | $58.81 | $79.78 | $21.25 | $57.34 |
| 2019 | $58.65 | $54.06 | $268.22 | $21.25 | $50.51 |
| 2020 | $90.19 | $107.45 | $2,231.66 | $51.41 | $283.62 |
| 2021 | $36.48 | $107.39 | $876.81 | $46.43 | $82.02 |
| 2022 | $9.69 | $29.25 | $15.90 | $2.23 | $115.14 |
| 2023 | $2.69 | $1.29 | $0.00 | $0.00 | $0.00 |
| 2024 | $5.77 | $39.56 | $0.00 | $0.00 | $0.00 |
| 2025 | $8.99 | $47.34 | $0.00 | $14.68 | $0.00 |
AI valuation
Our deep-learning model estimates Emergent BioSolutions Inc.'s (EBS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $47.34
- Current price
- $8.47
- AI upside
- +458.91%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.60
-57.5% upside
Graham-Dodd
$14.68
+73.36% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EBS | Emergent BioSolutions Inc… | $8.47 | 434.81M | +459% | -57% | +73% | — | 9.14 | 0.92 | 0.65 | 3.56 | — | 5.59 | 48.62% | 13.47% | 7.08% | 10.46% | 6.53% | 3.88% | 1.09 | 1.69 | 5.01 | 2.19 | 1.54 | -12583.00% | -2881.00% | 33799.00% | 32.60% | 1.29 | 16.09% | 0.00% | 0.00% | 48.82% | 8.47 | 5.41 | 1.14 | 1.49 |
| AQST | Aquestive Therapeutics, I… | $4.00 | 397.23M | +466% | -73% | — | — | -5.21 | -3.82 | 3.99 | -7.37 | -1.78 | -3.82 | 68.95% | -53.46% | -76.68% | 52.97% | 32.25% | -55.57% | -0.63 | -1.83 | 4.68 | 4.18 | 1.26 | 29231.00% | 1380.00% | 38702.00% | -15.63% | -1.90 | 37.66% | 0.00% | 0.00% | 18.71% | -6.38 | -5.46 | 3.41 | -3.77 |
| CMPS | COMPASS Pathways plc | $6.90 | 662.41M | — | — | — | — | -1.63 | 1.63 | — | -0.80 | — | 1.63 | 0.00% | — | — | -81.55% | -590.05% | -63.36% | 0.21 | -39.79 | 5.92 | 5.49 | 0.89 | -86.00% | — | 2231.00% | -47.22% | -3.50 | -394.64% | 0.00% | 0.00% | 0.00% | -0.67 | -1.00 | — | -2.75 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| ESPR | Esperion Therapeutics, In… | $3.35 | 661.73M | +1,302% | +27,124% | — | — | -6.11 | -0.81 | 0.95 | 100.78 | — | -0.81 | 79.36% | 16.37% | -15.57% | 12.27% | 177.11% | -18.83% | -1.52 | 0.92 | 1.37 | 0.91 | 58.98 | -8621.00% | 18566.00% | -8231.00% | -7.58% | -0.10 | -78.04% | 0.00% | 0.00% | 3.87% | 14.02 | -31.82 | 2.30 | -4.45 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| ORGO | Organogenesis Holdings In… | $3.21 | 407.39M | +1,529% | +5,869% | -5% | +241% | 10.27 | 1.27 | 0.67 | 5.43 | — | 1.45 | 73.57% | 7.92% | 10.09% | 10.81% | 15.37% | 6.75% | 0.27 | 19.59 | 3.62 | 3.11 | -0.17 | -160000.00% | 1704.00% | -68573.00% | -6.43% | -0.10 | -8.41% | 2.99% | 30.70% | 2.99% | 8.25 | -15.07 | 0.65 | 3.09 |
| PRTA | Prothena Corporation plc | $8.67 | 466.71M | +225% | -47% | — | +4,117% | -2.07 | 1.80 | 52.25 | -1.06 | -2.08 | 1.80 | 0.00% | -1905.82% | -2520.57% | -63.62% | -2799.76% | -55.86% | 0.05 | — | 7.72 | 7.53 | 1.46 | 9956.00% | -9283.00% | 889.00% | -32.36% | -4.01 | -2483.59% | 0.00% | 0.00% | 0.00% | -1.15 | -1.30 | 21.92 | 5.73 |
| RIGL | Rigel Pharmaceuticals, In… | $34.74 | 630.58M | +1,555% | +15% | -85% | +70% | 20.63 | 109.71 | 2.01 | 12.04 | — | -15.15 | 89.60% | 13.49% | 9.75% | -137.92% | -117.91% | 12.44% | 18.24 | 3.06 | 2.13 | 1.88 | 0.11 | -16875.00% | 5338.00% | -24981.00% | 8.61% | 0.50 | -159.09% | 0.00% | 0.00% | 9.58% | 14.19 | 11.05 | 1.92 | -8.42 |
| SIGA | SIGA Technologies, Inc. | $6.47 | 463.33M | +352% | -48% | — | -5% | 6.20 | 1.70 | 2.65 | 3.01 | — | 1.71 | 77.44% | 50.45% | 42.69% | 28.70% | 100.67% | 23.75% | 0.00 | — | 9.12 | 6.97 | -2.20 | -1263.00% | -86.00% | -4860.00% | 13.27% | 1.92 | 90.03% | 11.62% | 72.10% | 13.06% | 3.03 | 4.36 | 1.53 | 10.11 |
| SNDL | SNDL Inc. | $1.54 | 396.55M | +1,401% | +62% | -9% | — | -5.99 | 0.51 | 0.63 | -11.63 | — | 0.61 | 26.11% | -11.28% | -10.30% | -8.20% | -8.54% | -6.82% | 0.13 | -13.49 | 5.10 | 3.06 | 1.60 | -4162.00% | 126.00% | -27858.00% | 7.62% | 0.61 | 3.96% | 0.00% | 0.00% | 8.92% | -4.62 | 10.92 | 0.52 | 0.99 |
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- CEO
- Joseph C. Papa Jr.
- Employees
- 900
- Beta
- 2.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.60 ÷ $8.47) − 1 = -57.5% (DCF, example).